Clinical Trial

Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types

Study acronym: FAPIDO
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The aim of the project is to demonstrate superior detection ratio of \[18F\]AlF-FAPI-74 PET/CT compared to \[18F\]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma (clinical T1-4N0-3M0) and pancreatic ductal adenocarcinoma (clinical T1-4N0-2M0-1) and describe the clinical utility of \[18F\]AlF-FAPI-74 PET/CT in oncological patients with a clinically challenging situation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-14.
Status change: Not Yet Recruiting → Recruiting 2025-02-06
Trial Details
NCT Number NCT06782412
Lead Sponsor KU Leuven
Collaborators: University Hospital, Ghent, University Hospital, Antwerp, Universitaire Ziekenhuizen KU Leuven, Kom Op Tegen Kanker
Conditions Oesophageal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, FAP, Oncology, Oncologic Disorders
Enrollment 109 participants
Start Date 2025-02-06
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-07